Xenon Pharmaceuticals (NASDAQ: XENE) and Bioverativ (NASDAQ:BIVV) are both bio therapeutic drugs companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Profitability

This table compares Xenon Pharmaceuticals and Bioverativ’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenon Pharmaceuticals -4,268.70% -53.33% -50.07%
Bioverativ 40.44% 69.03% 40.94%

Analyst Ratings

This is a summary of current recommendations and price targets for Xenon Pharmaceuticals and Bioverativ, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals 0 0 2 0 3.00
Bioverativ 0 13 3 0 2.19

Xenon Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 53.85%. Bioverativ has a consensus target price of $62.92, suggesting a potential downside of 39.49%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Bioverativ.

Institutional & Insider Ownership

54.6% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.6% of Bioverativ shares are owned by institutional investors. 9.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Xenon Pharmaceuticals and Bioverativ’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenon Pharmaceuticals $1.80 million 32.50 -$22.99 million ($1.59) -2.04
Bioverativ $887.40 million 12.68 $439.60 million N/A N/A

Bioverativ has higher revenue and earnings than Xenon Pharmaceuticals.

Summary

Bioverativ beats Xenon Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

About Bioverativ

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.